Fulvestrant and the sequential endocrine cascade for advanced breast cancer

Following relapse on endocrine therapy for advanced, hormone receptor-positive breast cancer, it is common for patients to experience responses to alternative endocrine agents. Fulvestrant (‘Faslodex’) is a new type of endocrine treatment – an oestrogen receptor (ER) antagonist with no agonist effec...

Descripción completa

Detalles Bibliográficos
Autor principal: Johnston, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750772/
https://www.ncbi.nlm.nih.gov/pubmed/15094760
http://dx.doi.org/10.1038/sj.bjc.6601632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750772/
https://www.ncbi.nlm.nih.gov/pubmed/15094760
http://dx.doi.org/10.1038/sj.bjc.6601632

Ejemplares similares